Cercar
01/12/2022
Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease
Pagonabarraga, J, Perez-Gonzalez, R, Bejr-kasem, H, Marin-Lahoz, J, Horta-Barba, A, Martinez-Horta, S, Aracil-Bolanos, I, Sampedro, F, Campolongo, A, Rivas, E, Puig-Davi, A, Ruiz-Barrios, I, Perez-Perez, J, Pascual-Sedano, B, Kulisevsky, J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. PARKINSONISM & RELATED DISORDERS. 2022; 105DOI:10.1016/j.parkreldis.2022.05.020. PMID:35752549. IF:4.100(Q2/3D).
01/12/2022
Trial of Deferiprone in Parkinson's Disease
Devos, D, Labreuche, J, Rascol, O, Corvol, JC, Duhamel, A, Delannoy, PG, Poewe, W, Compta, Y, Pavese, N, Ruzicka, E, Dusek, P, Post, B, Bloem, BR, Berg, D, Maetzler, W, Otto, M, Habert, MO, Lehericy, S, Ferreira, J, Dodel, R, Tranchant, C, Eusebio, A, Thobois, S, Marques, AR, Meissner, WG, Ory-Magne, F, Walter, U, de Bie, RMA, Gago, M, Vilas, D, Kulisevsky, J, Januario, C, Coelho, MVS, Behnke, S, Worth, P, Seppi, K, Ouk, T, Potey, C, Leclercq, C, Viard, R, Kuchcinski, G, Lopes, R, Pruvo, JP, Pigny, P, Garcon, G, Simonin, O, Carpentier, J, Rolland, AS, Nyholm, D, Scherfler, C, Mangin, JF, Chupin, M, Bordet, R, Dexter, DT, Fradette, C, Spino, M, Tricta, F, Ayton, S, Bush, AI, Devedjian, JC, Duce, JA, Cabantchik, I, Defebvre, L, Deplanque, D, Moreau, C. Trial of Deferiprone in Parkinson's Disease. NEW ENGLAND JOURNAL OF MEDICINE. 2022; 387(22)DOI:10.1056/NEJMoa2209254. PMID:36449420. IF:158.500(Q1/1D).
16/05/2022
Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial
Pérez-López C., Hernández-Vara J., Caballol N., Bayes À., Buongiorno M., Lopez-Ariztegui N., Gironell A., López-Sánchez J., Martínez-Castrillo J.C., Sauco M A., López-Manzanares L., Escalante-Arroyo S., Pérez-Martínez D.A., Rodríguez-Molinero A.. Comparison of the Results of a Parkinson's Holter Monitor With Patient Diaries, in Real Conditions of Use: A Sub-analysis of the MoMoPa-EC Clinical Trial. Frontiers in Neurology. 2022; 13DOI:10.3389/fneur.2022.835249. PMID:35651347. IF:3.400(Q2/5D).
01/01/2022
Functional changes in prefrontal cortex following frequency-specific training
Bach-Morrow L., Boccalatte F., DeRosa A., Devos D., Garcia-Sanchez C., Inglese M., Droby A.. Functional changes in prefrontal cortex following frequency-specific training. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-24088-7. PMID:36434008. IF:4.600(Q2/4D).